Clinical Trials
15 trialsNCT05392608 2026-05-22
SEQUEL-Breast
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT04544189 2026-04-02
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT05101564 2026-02-12
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Stanford University
Phase 2 Completed
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT05090358 2025-10-27
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04216472 2025-09-30
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05625087 2025-08-20
SAFIR 03
UNICANCER
Phase 2 Active not recruiting
NCT04300790 2025-07-29
METALLICA
MedSIR
Phase 2 Completed
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT05966584 2024-08-29
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT03386162 2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2 Terminated
NCT02506556 2022-08-16
PIKNIC
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT01923168 2018-09-14
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Novartis
Phase 2 Completed